Synthesis of new 2′-deoxy-2′-fluoro-4′-azido nucleoside analogues as potent anti-HIV agents by Wang, Qiang et al.
Synthesis of new 2′-deoxy-2′-fluoro-4′-azido nucleoside
analogues as potent anti-HIV agents
Qiang Wanga, Weidong Hua, Shuyang Wanga, Zhenliang Pana, Le Taob, Xiaohe Guob,
Keduo Qianc, Chin-Ho Chend, Kuo-Hsiung Leec,e,*, and Junbiao Changa,*
aDepartment of Chemistry, Zhengzhou University, Zhengzhou 450001, PR China
bHena Key Laboratory of Fine Chemical, Zhengzhou 450002, PR China
cNatural Products Research Laboratories, UNC Eshelman School of Pharmacy, University of
North Carolina, Chapel Hill, NC 27599-7568, USA
dDepartment of Surgery, Duke University Medical Center, Durham, NC 27710, USA
eChinese Medicine Research and Development Center, China Medical University and Hospital,
Taichung, Taiwan
Abstract
We prepared 1-(4′-azido-2′-deoxy-2′-fluoro-β -D-arabinofuranosyl)cytosine (10) and its
hydrochloride salt (11) as potential antiviral agents based on the favorable antiviral profiles of 4′-
substituted nucleosides. Compounds 10 and 11 were synthesized from 1,3,5-O-tribenzoyl-2-
deoxy-2-fluoro-D-arabinofuranoside in multiple steps, and their structures were unequivocally
established by IR, 1H NMR, 13C NMR, and 19F NMR spectroscopy, HRMS, and X-ray
crystallography. Compounds 10 and 11 exhibited potent anti-HIV-1 activity (EC50: 0.3 and 0.13
nM, respectively) without significant cytotoxicity in concentrations up to 100 μM. Compound 11
exhibited extremely potent anti-HIV activity against NL4-3 (wild-type), NL4-3 (K101E), and
RTMDR viral strains, with EC50 values of 0.086, 0.15, and 0.11 nM, respectively. Due to the high
potency of 11, it was also screened against an NIH Reagent Program NRTI-resistant virus panel
containing eleven mutated viral strains and for cytotoxicity against six different human cell lines.
The results of this screening indicated that 11 is a novel NRTI that could be developed as an anti-
AIDS clinical trial candidate to overcome drug-resistance issues.
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Since the discovery of the human immunodeficiency virus (HIV) in 1983, AIDS has become
the leading infectious cause of death worldwide. According to the World Health
Organization (07 AIDS Epidemic Update), there were 33.2 million people living with AIDS
worldwide in 2007, 2.1 million deaths from AIDS, and 2.5 million newly infected patients
with AIDS. Over the last two decades, tremendous effort has been directed to the discovery
and development of novel agents for the treatment of HIV infections and great successes
have been achieved. So far, there are more than 20 approved anti-HIV drugs, belonging to
seven classes [1].
Nucleoside reverse transcriptase inhibitors (NRTIs) are one of the most important classes of
compounds active against HIV replication and have been used extensively to treat HIV
infection [2]. However, the long term use of antiviral nucleoside analogs is inevitably
associated with delayed toxicity and/or development of drug-resistant virus [3–6], which
limits their effectiveness as an AIDS treatment. Therefore, there remains a need for the
development of novel anti-HIV agents with better therapeutic indices, new mechanisms of
action, and activity against HIV strains resistant to currently available drugs.
All clinical NRTIs belong to the family of 2′,3′-dideoxynucleoside (ddN) [7]. As the chain
terminator of proviral DNA biosynthesis, the ddN structure has been assumed to be essential
for an active nucleoside derivative. However, resistant HIV variants and other side effects
have emerged. Resistance to these ddNs results from HIV mutants that have acquired the
ability to discriminate between ddN and physiologic 2′-deoxynucleoside (dN), do not accept
ddN into the active center of their reverse transcriptase (RT), and selectively cut off the
incorporated ddN from their proviral DNA terminus. Therefore, nucleoside drugs that could
prevent the emergence of drug-resistant HIV variants must have a 3′-OH as the chain
terminator of proviral DNA biosynthesis.
A 4′-C-substituted-2′-deoxynucleoside (4′sdN) satisfies these conditions, because 4′sdN has
all of the functional groups of dN, making it difficult for HIV to discriminate between a
4′sdN and dN. At the same time, the 3′-OH group of 4′sdN would not be useful for
elongation of proviral DNA biosynthesis. Thus, 4′sdN could be the chain-terminator of
proviral DNA biosynthesis and active against HIV as well as HIV strains resistant to current
ddN drugs. In addition, modification of the carbohydrate moiety of nucleosides with
electron-withdrawing groups can greatly affect the nucleoside’s electronic properties and
conformational shape [8–14], which often leads to dramatically improved activities.
Therefore, we incorporated a fluorine atom, which has the strongest electron-withdrawing
property of the halogens atoms, into our newly designed 4′sdN. Moreover, azido, cyano, and
ethynyl groups, which have characteristic electronic and structural features due to their sp
hybridization, are present in many biologically active compounds [15–17]. It has been
proposed that the furanose ring of 4′-C-azidothymidine exhibits an unnatural 3′-C-endo
conformation, and the compound was active against multidrug-resistant strains of HIV
(EC50: 0.34 μM) [18]. Therefore, we were interested in designing novel 4′sdN compounds
with such substitutions at the 4′-position. Herein, we report the synthesis and evaluation of
1-(4′-azido-2′-deoxy-2′-fluoro-β -D-arabinofuranosyl)cytosine (10) (Fig. 1) as a novel potent
NRTI that couldovercome drug -resistanceproblems [ 19–21].
2. Chemistry
The synthesis of 10 is illustrated in Scheme 1. According to the reported method [8, 13, 19–
25], treatment of commercially available 1,3,5-O-tribenzoyl-2-deoxy-2-fluoro-D-
arabinofuranoside (1) with HBr-HOAc (45%) in dichloromethane (DCM) gave exclusively
the α-bromide 2, which was coupled with silylated uracil in chloroform to provide the β -
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nucleoside analog 3 in a good yield after recrystallization. Deprotection of 3 with
methanolic ammonia afforded nucleoside 4 in excellent yield. The 4′-azido substitution was
introduced using the following procedure modified from the previously reported method
[26]. Treatment of 4 with I2/Ph3P in tetrahydrofuran (THF) followed by elimination in the
presence of sodium methoxide (NaOMe) gave 4′-methylene-nucleoside 6. Treatment of 6
with ICl/NaN3 in THF afforded 4′-azido-nucleoside 7. Benzoylation of 7 followed by
treatment with m-chloroperbenzoic acid (m-CPBA) in the presence of m-chlorobenzoic acid
(m-CBA) yielded a protected 4′-azido-uridine analog 9. Treatment of 9 with triazole/POCl3
followed by methanolic ammonia gave our target 10. Compound 10 was dissolved in
methanol and treated with a solution of hydrogen chloride in ethyl acetate. The product
separated as a solid and was collected by filtration to afford the hydochloride salt (11) of 10.
The solid-state structure of 11 was determined by single-crystal X-ray crystallography (Fig.
2). Crystallographic data (excluding structure factors) for the structures in this paper have
been deposited with the Cambridge Crystallographic Data Centre as supplementary
publication (nos. CCDC 740473). Copies of the data can be obtained, free of charge, on
application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK, (fax: +44-(0)1223-336033
or e-mail: deposit@ccdc.cam.ac.uk).
3. Results and discussion
The anti-HIV activity of 10 and 11 was first evaluated in vitro according to standard
procedures using efavirenz (EFV) and zidovudine (AZT) as controls (Table 1) [27–31].
Compounds 10 and 11 exhibited extremely potent antiviral activity with EC50 values of 0.3
and 0.13 nM, respectively, compared with EFV (EC50: 1.2 nM) and AZT (EC50: 47 nM).
The increased activity of 11 compared with 10 likely reflects its increased solubility of 11 in
water [32]. Both compounds did not show significant cytotoxicity in concentrations up to
100 μM against the MT-2 cell line using the MTT assay. In the further evaluation of 11, we
discovered that it retained its sub-nanomolar activity against drug-resistant HIV strains
NL4-3 (K101E) and RTMDR (Table 2). K101E tends to decrease viral susceptibility to all
nucleoside RT inhibitors, while RTMDR is a multiple RT inhibitor-resistant strain, which is
insensitive to AZT, ddI, nevirapine, and other NNRTIs. In our screening, 11 exhibited
extremely potent anti-HIV activity against NL4-3 (wild-type), NL4-3 (K101E), and
RTMDR, with EC50 values of 0.086, 0.15, and 0.11 nM, respectively. These findings
suggested that 11 has a great potential to be developed as a novel NRTI.
Therefore, in the following study, we further evaluated the anti-HIV potential of 11 using a
panel of eleven NRTI resistant viral strains from the NIH Reagent Program. As shown in
Table 3, 11 retained its nanomolar activity against resistant strains 7324-1, 7324-4, 7303-3,
35764-2, and 56252-1 with EC50 values of 0.595, 0.735, 0.56, 0.42, 0.525 nM, respectively,
which were similar to that of 11 against the wild type NL4-3 (EC50: 0.318 nM). However,
11 partially or completely lost its nanomolar inhibitory activity against 10076-4, 7295-1,
4755-5, 6463-13, 1617-1, and 29129-2. After carefully analyzing the mutations of these
resistant viral strains, we discovered that one single mutation M184V may lead to the
substantially reduced antiviral activity of 11. This M184V mutation in RT was discovered
previously to be 3TC treatment-associated, and it was also found that the M184V mutation
increases the HIV sensitivity to AZT in AZT-resistant viruses, suggesting that compound 11
may be used in combination with AZT to reduce the influence of resistance issues.
The cytotoxicity profiles of 11 were further evaluated using six human cell lines different
from the previously used MT-2 cell line (Table 4). A Promega CellTiter-Glo Luminescent
Cell Viability Assay was used to determine the number of viable cells based on quantitation
of the presence of ATP, which signals the presence of metabolically active cells. Compound
11 showed little cytotoxicity against TZM-BL, HEPG-2, and 293T cells with IC50 values
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over 140 μM, resulting in therapeutic index (TI) values of >280,000. Comparatively, 11
showed some cytotoxicity against MT4, ACH-2, and PBMC cells with IC50 values of 0.12,
0.11, and 0.15 μM, and corresponding TI values of 1418, 1255, and 1709. Overall, 11
showed less toxicity to adherent cells compared to suspension cells. Nevertheless, the TI
values were still greater than at least one thousand.
Regarding mechanism of action, compound 10 is likely to have a strong binding in the
active site of HIV RT due to the introduction of fluorine at the 2′-position. Although
compound 10 possesses a 3’-hydroxy group, it might act like a DNA chain terminator
similar to 4’-azido thymidine (Fig. 3). Based on the drug profile shown in Table 3 against
resistant virus strains, D67 and M184 are likely the two critical amino acid residues in the
NRTI binding site of HIV-1 RT that interact intimately with the compound. NRTI resistant
viruses with D67N or M184V mutation are markedly resistant to compound 10. Thus, the
compound is likely to bind between the palm and the finger subdomains of HIV-1 RT and
make critical interactions with residues including D67 and M184.
4. Conclusion
In summary, novel 4′sdN compounds 10 and 11 were designed, synthesized, and evaluated
for anti-HIV activity. The hydrochloride salt 11 retained its sub-nanomolar activity against
NRTI-resistant (K101E) and multi-drug-resistant HIV strains (RTMDR). In further studies,
11 also showed nanomolar activity against resistant viral strains, except for the M184V
single mutation. Compound 11 showed little cytotoxicity against adherent cells and marginal
cytotoxicity against suspension cells with TI values over one thousand. Overall, compound
11 merits further development as an anti-AIDS clinical trial candidate.
5. Experimental
All chemical reagents were commercially available and column chromatography was
performed on silica gel 200–300 mesh (Yantai Silica Gel Co. LTD). Analytical TLC was
performed on silica gel GF254. Melting points were recorded with an XT-4 melting point
apparatus and are uncorrected. IR spectra were obtained on a NICOLET 6700
spectrometer. 1H, 19F, and 13C NMR spectra were obtained with a Bruker AV-300
spectrometer. Chemical shifts are reported as δ (ppm) downfield with respect to an internal
standard of tetramethylsilane (TMS). High-resolution mass spectra (HRMS-ESI) were
obtained on a MicroTM Q-TOF Mass Spectrometer. Elemental analyses were performed
with a Carlo-Erba 1106 C, H, and N analyzer. LC-MS spectra were measured on an Agilent
MSD-1100 ESI-MS/MS system. X-ray crystallography was obtained on Rigaku Saturn 724
CCD diffractometer.
5.1. Synthesis of 1-(2-deoxy-2-fluoro-3,5-di-O-benzoyl-β-D-arabino-furanosyl)uracil (3)
To a solution of 1,3,5-O-tribenzoyl-2-deoxy-2-fluoro-D-arabinofuranoside (1) (20.0 g, 43.1
mmol) in anhydrous DCM (400 mL) was added HBr-HOAc (45% v/v, 50 mL, 271 mmol)
dropwise under nitrogen at 0 C and the resulting solution was stirred at room temperature for
20 h. The solution was washed with saturated NaHCO3 (3×100 mL), dried over Na2SO4,
filtered, and concentrated to give compound 2 as syrup, which was used in the next step
without further purification.
A mixture of uracil (12.6 g, 113.0 mmol) and (NH4)2SO4 (1.57 g) in hexamethyldisilazane
(HMDS) (1.5 L) was refluxed under nitrogen for 20 h, and the homogeneous solution
obtained was evaporated to dryness under vacuum to give the silylated uracil. To the
silylated uracil residue was added a solution of compound 2 in CHCl3 (800 mL) and the
mixture was refluxed under nitrogen for 24 h. The reaction was quenched by addition of ice-
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water and filtered. The aqueous layer was extracted with DCM (3×200 mL) and the
combined organic solution was washed with brine, dried over Na2SO4, filtered, and
concentrated to give a white solid, which was recrystallized with 5% EtOH-DCM to give
compound 3 (16.7 g, 84.2%). 1H NMR (300 MHz, CDCl3) δ 8.35 (1H, brs, NH), 7.43-8.11
(11H, m, Ar-H, H-6), 6.33 (1H, dd, J = 21.59, 2.93 Hz, H-1′), 5.69 (1H, d, J = 8.05 Hz,
H-5), 5.63 (1H, dd, J = 17.20, 2.93 Hz, H-3′), 5.34 (1H, dd, J = 50.13, 2.93 Hz, H-2′), 4.78
(2H, d, J = 4.39 Hz, H-5′), 4.52 (1H, m, H-4′); ESI- MS: m/z 455 [M+H]+; Anal. calcd
(C23H19FN2O7): C, 60.79; H, 4.21; N, 6.16; found: C, 60.75; H, 4.24; N, 6.11.
5.2. Synthesis of 1-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)uracil (4)
A solution of compound 3 (7.79 g, 17.1 mmol) in saturated NH3-MeOH (200 mL) was
stirred at room temperature for 24 h and evaporated to dryness under reduced pressure.
DCM (25 mL) was added to the residue and the mixture was stirred at room temperature for
1 h. The white solid was collected by filtration to give compound 4 (3.93 g, 93.0%). 1H
NMR (300 MHz, DMSO-d6) δ 11.35 (1H, brs, NH), 7.71 (1H, dd, J = 8.05, 1.46 Hz, H-6),
6.10 (1H, dd, J = 16.10, 4.39 Hz, H-1′), 5.87 (1H, d, J = 5.12 Hz, 3′-OH), 5.64 (1H, d, J =
8.05 Hz, H-5), 5.08 (1H, t, J = 5.85 Hz, 5′-OH), 5.03 (1H, ddd, J = 52.69, 4.03, 2.93 Hz,
H-2′), 4.21 (1H, dm, J = 19.76 Hz, H-3′), 3.79 (1H, m, H-4′), 3.60 (2H, m, H-5′); ESI-MS:
m/z 269 [M+Na]+; Anal. calcd (C9H11FN2O5): C, 43.91; H, 4.50; N, 11.38;found : C, 43.90;
H, 4.29; N, 11.33.
5.3. Synthesis of 1-(2,5-dideoxy-2-fluoro-5-iodo-β-D-arabino-furanosyl)uracil (5)
To a solution of compound 4 (3.73 g, 15.2 mmol), imidazole (2.06 g, 30.3 mmol), and
triphenylphosphine (5.96 g, 22.7 mmol) in THF (100 mL) was added a solution of iodine
(5.77 g, 22.7 mmol) in THF (50 mL) dropwise at 0 °C. The reaction mixture was stirred at
room temperature overnight and quenched with a saturated solution of Na2SO3, extracted
with EtOAc (2×100 mL). The combined organic solution was washed with water, brine,
dried over Na2SO4, filtered, and concentrated to yield a thick oil, which was purified by
silica gel column chromatography (1–5% MeOH in DCM) to afford compound 5 (4.51 g,
83.5%). 1H NMR (300 MHz, DMSO–d6) δ 11.50 (1H, br s, NH), 7.58 (1H, dd, J = 8.14,
1.95 Hz, H-6), 6.17 (1H, dd, J = 18.40, 3.99 Hz, H-1′), 6.15 (1H, br, 3’-OH), 5.67 (1H, d, J
= 8.14Hz, H-5), 5.08 (1H, ddd, J = 52.41, 3.84, 2.55 Hz, H-2′), 4.14 (1H, ddd, J = 19.68,
4.21, 2.65 Hz, H-3′), 3.87 (1H, dd, J = 11.02, 5.19 Hz, H-4′), 3.43-3.57 (m, 2H); 13C NMR
(75 MHz, DMSO-d6) δ 6.2, 76.7, 82.0, 83.0, 95.3, 101.4, 141.2, 150.0, 162.8; ESI-MS: m/z
379 [M+23]+; Anal. calcd (C9H10FIN2O4): C, 30.36; H, 2.83; N, 7.87; found: C, 30.30; H,
2.88; N, 7.84.
5.4. Synthesis of 1-(2,5-dideoxy-2-fluoro-β-D-arabino-4-eno-furanosyl)uracil (6)
A solution of compound 5 (4.2 g, 11.8 mmol) in dry MeOH (40 mL) containing MeONa
(25%wt in MeOH, 10.2 mL, 47.3 mmol) was heated to 65 °C for 3 h and an additional
aliquot of MeONa (25%wt in MeOH, 3.4 mL) was added. After 30 min, the reaction mixture
was allowed to stay at room temperature overnight and brine was added. The mixture was
adjusted to pH 3 by addition of 1N HCl and the mixture was extracted with EtOAc (2×300
mL). The combined organic solution was dried over Na2SO4, filtered, and concentrated. The
residue was purified by silica gel column chromatography (2–5% MeOH in DCM) to afford
compound 6 (1.94 g, 72.1%). 1H NMR (300 MHz, CDCl3) δ 9.05(1H, br s, NH), 7.32 (1H,
dd, J = 8.16, 2.31 Hz, H-6), 6.62 (1H, dd, J = 20.97, 2.79 Hz, H-1′), 5.76 (1H, d, J = 8.22Hz,
H-5), 5.09 (1H, dd, J = 51.44, 2.95 Hz, H-2′), 4.76 (1H, d, J = 2.74 Hz, =CH2 ), 4.73 (1H, d,
J = 11.46 Hz, H-3′), 4.52 (1H, d, J =2.74Hz, =CH2); ESI-MS: m/z 227 [M-H]+; Anal. calcd
(C9H9FN2O4): C, 47.37; H, 3.98; N, 12.28;found : C, 47.43; H, 3.86; N, 12.13.
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5.5. Synthesis of 1-(4-azido-2,5-dideoxy-2-fluoro-5-iodo-β-D-arabino-furanosyl)uracil (7)
To a suspension of NaN3 (1.38 g, 21.3 mmol) in THF (50 mL) at 0 °C was added ICl (2.31
g, 14.2 mmol). After 10 minutes, a solution of compound 6 (1.62 g, 7.10 mmol) in THF (16
mL) was added dropwise to the mixture and the reaction mixture was stirred at room
temperature overnight. Aqueous Na2SO3 solution was added and the mixture extracted with
EtOAc (3×250 mL). The combined organic solution was dried over Na2SO4, filtered, and
concentrated. The residue was purified by silica gel column chromatography (1–5% MeOH
in DCM) to afford compound 7 (1.82 g, 64.6%). IR KBr): 2119 cm−1(N3); 1H NMR (300
MHz, MeOH-d4) δ 7.68 (1H, dd, J= 8.1 6, 1.87 Hz, H-6), 6.46 (1H, dd, J= 16.07 , 4.39 Hz,
H-1′), 5.74(1H, d, J= 8. 12 Hz, H-5), 5.22 (1H, ddd, J = 52.93, 4.36, 3.30 Hz, H-2′), 4.65
(1H, dd, J = 18.67, 3.31 Hz, H-3′), 3.69 (2H, m, H-5′); ESI-MS: m/z 420 [M+23]+; Anal.
calcd (C9H9FIN5O4): C, 27.22; H, 2.28; N, 17.64;found : C, 27.09; H, 2.23; N, 17.73.
5.6. Synthesis of 1-(4-azido-2,5-dideoxy-2-fluoro-3-O-benzoyl-5-iodo-β-D-
arabinofuranosyl)uracil (8)
To a solution of compound 7 (1.17 g, 2.95 mmol) in DCM (130 mL) were added Et3N (0.82
mL, 5.90 mmol) and a catalytic amount of 4-dimethylaminopyridine. The reaction mixture
was cooled to 0° C and benzyl chloride (0.41 mL, 3.54 mmol) was added. After 20 min,
water and 2M K2CO3 were added, and the mixture was extracted with EtOAc (400 mL).
The organic layer was washed with brine (2×50 mL), dried over Na2SO4, filtered, and
concentrated. The residue was purified by silica gel column chromatography (0.1–1%
MeOH in DCM) to afford compound 8 (1.2 g, 81.2%). IR (KBr): 2118 cm−1(N3); 1H NMR
(300 MHz, DMSO-d6) δ 11.63 (1H, br s, NH), 7.57–8.09 (6H, m, Ar-H and H-6), 6.52 (1H,
dd, J = 18.69, 5.52 Hz, H-1′), 6.07 (1H, dd, J = 21.57, 4.05 Hz, H-3′), 5.82 (1H, ddd, J =
52.21, 5.32, 4.38 Hz, H-2′), 5.78 (1H, d, J = 8.14 Hz, H-5), 3.99 (2H, q, J = 11.66 Hz, H-5′);
ESI-MS: m/z 524 [M+23]+; Anal. calcd (C16H13FIN5O5): C, 38.34; H, 2.61; N,
13.97;found : C, 38.26; H, 2.48; N, 13.85.
5.7. Synthesis of 1-(4-azido-2-deoxy-2-fluoro-3-O-benzoyl-5-O-(3-chlorobenzoyl)-β-D-
arabinofuranosyl)uracil (9)
To a solution of 8 (1.10 g, 2.19 mmol) in DCM (100 mL) and water (60 mL) were added
successively K2HPO4 (0.76 g, 4.38 mmol), n-Bu4NHSO4 (0.82 g, 2.41 mmol), and m-CBA
(0.38 g, 2.41 mmol). The reaction mixture was cooled to 0 °C and m-CPBA (77%, 1.47 g,
6.57 mmol) was added. The reaction mixture was stirred at room temperature overnight.
Na2SO3 was added and the mixture was extracted with EtOAc (500 mL). The combined
organic solution was washed with Na2SO3 (5%), brine, dried over Na2SO4, filtered, and
concentrated. The residue was purified by silica gel column chromatography (0.1–0.5%
MeOH in DCM) to provide compound 9 (667 mg, 57.5%). IR (KBr): 2117 cm−1 (N3); 1H
NMR (300 MHz, CDCl3) δ 7.41–8.10 (10H, m, Ar-H and H-6), 6.63(1H, dd, J = 18.36, 3.61
Hz, H-1′), 5.73–5.84(2H, m, H-3′ and H-5), 5.45 (1H, ddd, J = 51.37, 3.55, 2.03 Hz, H-2′),
4.86 (2H, q, J = 11.87 Hz, H-5′); ESI-MS: m/z553 [M+23] +;Anal. c alcd (C23H17FClN5O7):
C, 52.14; H, 3.23; N, 13.22;found : C, 52.03; H, 3.22; N, 13.00.
5.8. Synthesis of 1-(4-azido-2-deoxy-2-fluoro)-β-D-arabinofuranosyl)cytosine (10)
To a solution of compound 9 (0.40 g, 0.75 mmol) in DCM (15 mL) was added 1,2,4-triazole
(0.57 g, 8.25 mmol) followed by pyridine (0.67 mL, 8.25 mmol). The solution was cooled to
0 °C and POC13 (0.39 mL, 3.75 mmol) was added. The solution was stirred at 0 °C for 2 h
then room temperature overnight. The reaction was quenched with water and the mixture
was extracted with DCM (2×250 mL). The combined organic solution was dried over
Na2SO4, filtered, and concentrated. The residue was dissolved in THF (40 mL) and NH4OH
(33%, 40 mL) was added. The reaction mixture was stirred at room temperature for 1 h.
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Solvent was removed and the residue was dissolved in MeOH (40 mL) and 7N NH3 in
MeOH (40 mL) was added. The solution was stirred at room temperature overnight. The
solution was concentrated to dryness under reduced pressure and the residue was purified by
silica gel column chromatography (1–5% MeOH in DCM) to give compound 10 (92 mg,
41.1%) as a white solid. mp: 86–87 °C; IR (KBr): 2118 cm−1 (N3); 1H NMR (300 MHz,
MeOH-d4) δ 7.80 (1H, d, J = 7.57Hz, H-6), 6.50 (1H, dd, J = 12.10, 4.67 Hz, H-1’), 5.97
(1H, d, J = 7.57Hz, H-5), 5.21 (1H, dt, J = 53.52, 4.48 Hz, H-2′), 4.49 (1H, dd, J = 21.63,
4.34 Hz, H-3′), 3.84 (2H, s, H-5′); 13C NMR (75.47 MHz, MeOH-d4) δ 63.4, 76.5 (J = 25.2
Hz), 84.8 (J = 17.2 Hz), 96.1, 96.2 (J = 193.4 Hz), 98.6 (J = 7.5 Hz), 143.0, 157.9,
167.8; 19F NMR (282.4 MHz, MeOH-d4): -202.5; ESI-TOF/MS for C9H11FN6O4: calcd
287.0904 [M+H]+; found: 287.0905[M+H]+; Anal. calcd (C9H11FN6O4): C, 37.77; H, 3.87;
N, 29.36; found: C, 37.53; H, 3.90; N, 29.19.
5.9. Synthesis of 1-(4-azido-2-deoxy-2-fluoro)-β-D-arabinofuranosyl)cytosine hydrochloride
salt (11)
Compound 10 (50 mg, 0.17 mmol) was dissolved in MeOH (1 mL) and treated with a
solution of hydrogen chloride (20 mmol) in EtOAc (10 mL). The product separated as a
solid and was collected by filtration to afford the hydrochloride salt of compound 10 (34 mg,
61.1%). IR (KBr): 2117 cm−1 (N3); 1H-NMR (D2O) δ 7.94 (1H, dd, J = 8.05, 1.10 Hz, H-6),
6.54 (1H, dd, J = 10.98, 5.12 Hz, H-1′), 6.26 (1H, d, J = 8.05 Hz, H-5), 5.39 (1H, dt, J =
52.69, 5.12 Hz, H-2′), 4.58 (1H, dd, J = 21.59, 4.76 Hz, H-3′), 3.97 (2H, q, J = 12.66 Hz,
H-5′); ESI-MS: m/z 287 [M+H]+.
5.10. Single-crystal X-ray diffraction analysis of hydrochloride salt 11
C9H11FN6O4·HCl, fw = 322.70, Monoclinic P2(1), a = 6.5738(13) Å, b = 14.309(3) Å, c =
7.3271(15) Å, α = γ = 90°, β = 99.68(3)°, V = 679.4(2) Å3,Z = 2, ρcalcd = 1.577 Mg/m3,
λ(Mo-Kα)= 0.71073Å, μ = 0.320 mm−1, F(000) = 332, T = 293(2). A colorless 0.22 × 0.18 ×
0.14 mm3 crystal was used for data collection. The theta range for data collection was 3.14
to 26.01° with 2633 reflections collected.
5.11. Anti-HIV (wt) activity assay
Vesicular stomatitis virus glycoprotein (VSV-G) plasmid was co-transfected with env-
deficient HIV vector, pNL4-3.luc.R−E− [24, 25], into 293 cells by using modified
Ca3(PO4)2 method.26 Briefly, 293 cells (100 mm plate) were transfected with 8 μg HIV
vector alone or with 3 μg VSVG DNA. After 16 h, plates were washed with phosphate-
buffered saline, and fresh medium was added into the plates. After post-infection for 48 h,
the supernatant was harvested and filtered through a 0.45 μm filter. The supernatant contains
VSVG/HIV pseudotyped virions and can be used directly or stored at −80 °C.
One hour prior to infection, MT-2 cells were plated on 24-well plates at the density of
1.2×105 cells per well. Compound was incubated with target cells for 15 minutes prior to
adding VSVG/HIV-1 (0.5 mL/well) for infection. The same amount of solvent alone was
used as control. After post-infection for 48 h, cells were spin down and supernatant was
discarded. Cells were lysed in 50 μl Cell Lysis Reagent (Promega). Luciferase activity of the
cell lysate was measured by a FB15 luminometer (Berthold Detection System) according to
the manufacturer’s instructions. Compounds 10 and 11 showed dose-dependent inhibition
activity on HIV-1 replication with EC50 values of 0.3 nM and 0.13 nM, respectively, and
thus, were more potent than AZT (EC50: 47 nM).
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5.12. Cell viability assay
Compounds 10 and 11 were evaluated for cell viability by MTT methods [27]. MTT assay
was performed in MT-2 cell line. Both compounds had no significant effect on cell growth
or any cytotoxic effect on MT-2 cells at a final concentration of 100 μM.
5.13. Anti-HIV replication assay against NL4-3 (K101E) and RTMDR strains in TZM-bl cell
lines
A previously described HIV-1 infectivity assay was used in the experiments [28]. A 96-well
cell culture plate was used to set up the virus replication screening sassy. NL4-3 (K101E) or
RTMDR at a multiplicity of infection (MOI) of 0.001 was used to infect TZM-bl cells.
Culture supernatants were collected on day 4 post-infection for a p24 assay using an ELISA
kit from PerkinElmer.
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Structures of 1-(4′-Azido-2′-deoxy-2′-fluoro-β -D-arabinofuranosyl)cytosine (10) and Its
Design Lead 4′-Azido-thymidine.
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X-ray Crystallographic Structure of Hydrochloride Salt 11.
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Mechanism of Phosphorylated Compound 10.
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Reagents and conditions: a) HBr/HOAc/DCM; b) silylated uracil(5-fluorouracil)/CHCl3; c)
NH3/MeOH; d) Ph3P/I2/DMF; e) NaOMe/THF; f) ICl/NaN3/THF; g) BzCl/Pyr.DCM; h)
mCPBA/mCBA/DCM; i) 1. triazole/POCl3/pyridine/DCM, 2. NH4OH, 3. NH3/MeOH; j)
HCl, MeOH, EtOAc.
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Table 1
Anti-HIV activity of 10 and 11 against wild-type HIV-1 virus.






EC50 (nM) is the concentration that inhibits HIV by 50%. Results were averaged from at least two separate experiments.
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Table 2
Anti-HIV activity of 11 against NL4-3 (wild-type), NL4-3 (K101E), and RTMDR.





EC50 (nM) is the concentration that inhibits HIV by 50%. Results were averaged from at least two separate experiments.













Wang et al. Page 17
Table 3
Anti-HIV activity of compound 11 against NIH reagent program NRTI-resistant virus panel.
NRTI Resistant Virus Panel EC50 (nM) a
7324-1 (M41L, D67N, K70R, T215F, K219E, T69N) 0.595
7324-4 (M41L, K70R, T215F, K219E) 0.735
10076-4 (M41L, T215Y, M184V) >40,000 b
7295-1 (D67N, K70R, T215F, K219Q, M184V, T69N) >40,000
4755-5 (M41L, D67N, L210W, T215Y, M184V, T69D, E44D, V118I) >40,000
6463-13 (M41L, D67N, L210W, T215Y, M184V, V118I) >40,000
7303-3 (M41L, D67N, L210W, T215Y, T69D, E44D, V118I) 0.56
1617-1 (K70G, M184V, T69K, V75I, F77L, F116Y, Q151M) 32.2
35764-2 (V75I, F77L, F116Y, Q151M) 0.42
29129-2 (M41L, D67N, L210W, T215Y, M184V) >40,000
56252-1 (K70R, V75I, F77L, F116Y, Q151M, K65R) 0.525
NL4-3 (wild-type) 0.318
a
EC50 (nM) is the concentration that inhibits HIV by 50%. Results were averaged from at least two separate experiments.
b
The highest concentration tested was 40,000 nM.
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Table 4
Cytotoxicity screening of compound 11 against six human cell lines.
Cells IC50 (μM) a





PBMC (PHA activated) 0.15
a
IC50 (μM) is the concentration that inhibits cell growth by 50%. Results were averaged from at least three separate experiments.
b
The highest concentration tested was 140 μM.
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